Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.78 |
| ▸ | ANPEP | P15144 | 2/20 | 0.78 |
| ▸ | ECE1 | P42892 | 1/20 | 0.54 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12609403 | 1.00 | MME (0.78) | MMEANPEPECE1ENPEP | |
| SCHEMBL20526394 | 0.92 | MME (0.67) | MMEANPEPECE1 | |
| SCHEMBL29684736 | 0.87 | MME (1.00) | MMEANPEP | |
| SCHEMBL20526397 | 0.87 | MME (1.00) | MMEANPEP | |
| SCHEMBL1764418 | 0.87 | MME (1.00) | MMEANPEP | |
| SCHEMBL4992398 | 0.87 | MME (1.00) | MMEANPEP | |
| SCHEMBL4992386 | 0.87 | MME (1.00) | MMEANPEP | |
| SCHEMBL12609398 | 0.87 | MME (1.00) | MMEANPEP | |
| SCHEMBL20526396 | 0.87 | MME (0.60) | MMEANPEPECE1ENPEP | |
| SCHEMBL1764058 | 0.86 | ANPEP (0.57) | MMEANPEPENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3592361-B1 | AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING OCULAR INFLAMMATION | IACTA PHARMACEUTICALS INC (PR) | 2023-09-13 | — | — | EP | claimed |
| US-11090317-B2 | Aminophosphinic derivatives for preventing and treating eye inflammation | PHARMALEADS (FR) | 2021-08-17 | — | — | US | claimed |
| US-20210213036-A1 | AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING EYE INFLAMMATION | PHARMALEADS (FR) | 2021-07-15 | — | — | US | claimed |
| US-10688113-B2 | Methods of treating eye pain with aminophosphinic derivatives | PHARMALEADS (FR) | 2020-06-23 | — | — | US | claimed |
| US-20190167701-A1 | Methods of Treating Eye Pain With Aminophosphinic Derivatives | PHARMALEADS (FR) | 2019-06-06 | — | — | US | claimed |
| US-20180344753-A1 | AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING EYE PAIN | PHARMALEADS (FR) | 2018-12-06 | — | — | US | claimed |
| EP-3383403-A1 | AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING EYE PAIN | Pharmaleads (FR) | 2018-10-10 | — | — | EP | claimed |
| EP-3592361-B1 | AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING OCULAR INFLAMMATION | IACTA PHARMACEUTICALS INC (PR) | 2023-09-13 | — | — | EP | disclosed |
| US-11090317-B2 | Aminophosphinic derivatives for preventing and treating eye inflammation | PHARMALEADS (FR) | 2021-08-17 | — | — | US | disclosed |
| US-20210213036-A1 | AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING EYE INFLAMMATION | PHARMALEADS (FR) | 2021-07-15 | — | — | US | disclosed |
| US-10688113-B2 | Methods of treating eye pain with aminophosphinic derivatives | PHARMALEADS (FR) | 2020-06-23 | — | — | US | disclosed |
| US-20190167701-A1 | Methods of Treating Eye Pain With Aminophosphinic Derivatives | PHARMALEADS (FR) | 2019-06-06 | — | — | US | disclosed |
| US-20180344753-A1 | AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING EYE PAIN | PHARMALEADS (FR) | 2018-12-06 | — | — | US | disclosed |
| US-10131681-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | PHARMALEADS (FR) | 2018-11-20 | — | — | US | disclosed |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS (FR) | 2014-06-12 | — | — | US | disclosed |
| US-8703747-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | PHARMALEADS (FR) | 2014-04-22 | — | — | US | disclosed |
| US-20110124601-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167701-A1 | Methods of Treating Eye Pain With Aminophosphinic Derivatives | P2RX7, HRH3, P2RX6 | MME 3364/4885ANPEP 1779/4885ECE1 2402/4885 |
| US-20210213036-A1 | AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING EYE INFLAMMATION | C5, CDK7, MAPK7 | MME 3059/4885ANPEP 1237/4885ECE1 514/4885 |
| US-20110124601-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | OPRM1, HRH3, HRH4 | MME 3670/4885ANPEP 2038/4885ECE1 4157/4885 |
| US-10688113-B2 | Methods of treating eye pain with aminophosphinic derivatives | P2RX7, HRH3, P2RX6 | MME 3364/4885ANPEP 1779/4885ECE1 2402/4885 |
| US-11090317-B2 | Aminophosphinic derivatives for preventing and treating eye inflammation | C5, CDK7, MAPK7 | MME 3059/4885ANPEP 1237/4885ECE1 514/4885 |
| US-20180344753-A1 | AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING EYE PAIN | P2RX7, P2RY6, HRH3 | MME 3636/4885ANPEP 973/4885ECE1 2333/4885 |
| US-10131681-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | OPRM1, HRH3, HRH4 | MME 3490/4885ANPEP 2062/4885ECE1 4097/4885 |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | OPRM1, HRH3, HRH4 | MME 3490/4885ANPEP 2062/4885ECE1 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.